Evidence map›Paper›PMID 24026758›Full record

ReviewPediatric nephrology (Berlin, Germany)2014

Cardiovascular changes during chronic hypertensive states.

Dorota Drozdz, Kalina Kawecka-Jaszcz

Abstract readReview
In one paragraph

Review in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Brain and cardiovascular-related changes are associated with aging, hypertension, and atrial fibrillation.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.International journal of molecular sciences · 2020
    Review
  14. Article
  15. Article
  16. Unsolved Problem: (Isolated) Systolic Hypertension with Diastolic Blood Pressure below the Safety Margin.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. MiR-204 regulates type 1 IPCell calcium · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dorota DrozdzDialysis Unit, Jagiellonian University Medical College, 265 Wielicka Str., 30-663, Krakow, Poland, dadrozdz@cm-uj.krakow.pl.
Kalina Kawecka-Jaszcz

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well established that elevated blood pressure constitutes a major risk factor for coronary heart disease, arrythmias, heart failure, cerebrovascular disease, peripheral artery disease and renal failure. Blood pressure level and the duration of arterial hypertension (HTN) impact target organ damage. Many studies in adults have demonstrated the role of antihypertensive therapy in preventing cardiovascular (CV) events. The so-called hard end-points, such as death, myocardial infarction (MI) or stroke, are rarely seen in children, but intermediate target organ damage, including left ventricular hypertrophy, increased intima-media thickness and microalbuminuria, is already detectable during childhood. The goal of antihypertensive treatment is to reduce the global risk of CV events. In the adult population stratification of CV risk is based on blood pressure level, risk factors, subclinical target organ damage and established CV and kidney disease. Increased CV risk begins early in the course of kidney disease, and CV diseases are the most frequent cause of morbidity and mortality in patients with chronic kidney disease (CKD). Children with CKD are especially prone to the long-term effects of CV risk factors, which result in high morbidity and mortality in young adults. To improve the outcome, pediatric and adult CKD patients require nephro- and cardioprotection.

Indexed as

Antihypertensive AgentsCardiovascular DiseasesChildChronic DiseaseHumansHypertensionRenal Insufficiency, ChronicRisk FactorsAntihypertensive Agents

Identifiers

PMID24026758
PMCPMC4147208

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.